Skip to main content
FDA Panel Recommends Donanemab Approval
Breaking News
Health 36 minutes ago

FDA Panel Recommends Donanemab Approval

A U.S. FDA advisory committee has unanimously recommended approval for Eli Lilly's donanemab, an Alzheimer's drug that offers renewed hope by effectively slowing cognitive decline in patients with early-stage disease. This significant 11-0 decision, targeting amyloid plaques, moves the treatment closer to widespread availability and awaits the FDA's final ruling later this year, potentially expanding crucial options for those battling the neurodegenerative condition.

Catamist Editorial

Latest Updates

More Articles

Accessibility Options

Font Size

100%

High Contrast

Reading Preferences

Data & Privacy